 One of the toughest decision for a cancer patient is to select the right therapy to undergo after their diagnosis. We have taken an approach to generate models for every patient and characterize their therapeutic response using these models. We call these models organoids because they grow just like many organs in a dish and they're derived from cancer cells that are taken from either surgical resection or biopsy taken from the patient at the time of diagnosis. Organoids faithfully represent the genetics of the patient from which they are derived from. This is very important because we use organoids to derive signatures for therapeutic response in patients and we can use these signatures to then predict the therapeutic outcome of other patients if they're provided similar drugs. For instance, we use these organoids in the laboratory to characterize the therapeutic response to standard of care chemotherapy. This is particularly important because the options that are currently available to pancreas cancer patients are few and they present with a lot of toxicity. Selecting the right chemotherapy for the correct patient is extremely important because it will give the patient the best chance at long-term survival. The hope is to take this model forward as a precision medicine tool to guide therapeutics in the clinic.